HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

T Ruggiero; E. Burdino; Andrea CALCAGNO; Stefano BONORA; Lucio BOGLIONE; Giovanni DI PERRI; V. Ghisetti

doi:10.1007/s15010-016-0937-4

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

T Ruggiero
, E. Burdino
, Andrea CALCAGNO
, Stefano BONORA
, Lucio BOGLIONE
, Giovanni DI PERRI
, V. Ghisetti

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce. Methods: NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-naïve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection). Results: NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-naïve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162–2.916). Conclusions: HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.

Original language	English
Pages (from-to)	1-4
Number of pages	4
Journal	Infection
DOIs	https://doi.org/10.1007/s15010-016-0937-4
Publication status	Published - 2016

Keywords

DAAs
HIV/HCV coinfected
Hepatitis C virus
Infectious Diseases
Microbiology (medical)
RAVs

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s15010-016-0937-4

http://hdl.handle.net/11579/113955

Cite this

@article{d658702f33ba4cfbb2cd88811d4572be,

title = "HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-na{\"i}ve patients: consideration for HCV genotyping resistance testing",

abstract = "Purpose: Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce. Methods: NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-na{\"i}ve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection). Results: NS3 RAVs were identified in 31.5 \% of patients, with a significant proportion of HIV/HCV coinfected DAA-na{\"i}ve patients compared to those with HCV monoinfection (38 vs. 25 \% p = 0.0104, OR 1.84; 95 \% CI 1.162–2.916). Conclusions: HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.",

keywords = "DAAs, HIV/HCV coinfected, Hepatitis C virus, Infectious Diseases, Microbiology (medical), RAVs, DAAs, HIV/HCV coinfected, Hepatitis C virus, Infectious Diseases, Microbiology (medical), RAVs",

author = "T Ruggiero and E. Burdino and Andrea CALCAGNO and Stefano BONORA and Lucio BOGLIONE and \{DI PERRI\}, Giovanni and V. Ghisetti",

note = "Publisher Copyright: {\textcopyright} 2016, Springer-Verlag Berlin Heidelberg.",

year = "2016",

doi = "10.1007/s15010-016-0937-4",

language = "English",

pages = "1--4",

journal = "Infection",

issn = "0300-8126",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

AU - Ruggiero, T

AU - Burdino, E.

AU - CALCAGNO, Andrea

AU - BONORA, Stefano

AU - BOGLIONE, Lucio

AU - DI PERRI, Giovanni

AU - Ghisetti, V.

PY - 2016

Y1 - 2016

N2 - Purpose: Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce. Methods: NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-naïve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection). Results: NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-naïve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162–2.916). Conclusions: HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.

AB - Purpose: Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce. Methods: NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-naïve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection). Results: NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-naïve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162–2.916). Conclusions: HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.

KW - DAAs

KW - HIV/HCV coinfected

KW - Hepatitis C virus

KW - Infectious Diseases

KW - Microbiology (medical)

KW - RAVs

KW - DAAs

KW - HIV/HCV coinfected

KW - Hepatitis C virus

KW - Infectious Diseases

KW - Microbiology (medical)

KW - RAVs

UR - https://iris.uniupo.it/handle/11579/113955

U2 - 10.1007/s15010-016-0937-4

DO - 10.1007/s15010-016-0937-4

M3 - Article

SN - 0300-8126

SP - 1

EP - 4

JO - Infection

JF - Infection

ER -

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this